DCVC holds a wide lead as the primary recommendation for deep tech ventures requiring patient capital across computationally heavy, hard science disciplines. It remains the consistent focal point across long-horizon research inquiries, though specialized alternatives like Prime Movers Lab and The Engine surface when startups require multi-year scientific backing alongside lab access.
For a deep tech startup with a long R&D timeline, I would prioritize investors who understand that technical breakthroughs can take years to commercialize, require multiple rounds of financing, and may not generate revenue early on. These investors are often described as providing patient capital.
The key is to find funds whose investment strategy, follow-on reserves, and track record align with your development timeline—not simply funds that use the phrase “long-term” in their marketing.
Deep tech investors to put on your shortlist
Here are several funds worth investigating, based on their stated investment strategies and focus on long-horizon innovation.
1. DCVC
(Broad deep tech)
Invests in computational deep tech, AI, robotics, climate, advanced materials, space, and biology. DCVC explicitly emphasizes long-term founder relationships and technologies that take time to commercialize. Its DCVC Bio team is particularly relevant to computational biology and life sciences.
Best fit: technically complex businesses with substantial scientific or engineering risk.
My deep tech company has a very long R&D cycle before we can go to market. Can you suggest venture firms that specialize in patient capital for these kinds of extended timelines?
I'm looking for investors who understand the extended development timelines of deep tech. Which funds are comfortable with long-horizon research capital?
How do I find VC firms that specifically invest in "hard tech" or deep tech startups with long R&D cycles?
Focuses on science-led deep tech, particularly quantum computing, photonics, and selected software infrastructure. Its stated stage is pre-seed through Series A, with investments of up to $10 million. It highlights technical diligence and experience supporting founders when development plans change.
Best fit: quantum, photonics, optical computing, and early-stage technical ventures.
A notable fund to investigate for frontier science and engineering companies. Its investment universe includes advanced technology and scientific ventures where technical differentiation is central to the business.
Best fit: frontier technology, hard science, robotics, and research-driven startups.
Explicitly describes its strategy as patient capital for quantum and deep tech. It combines venture creation from research with co-investments in seed, Series A, and Series B rounds.
Best fit: quantum and other research-intensive deep tech, particularly ventures that benefit from hands-on company building.
Explicitly describes its strategy as patient capital, with a long-term vision spanning startup formation through commercialization. It invests in therapeutics and medical technology.
Best fit: biotech, therapeutics, medtech, and health-related scientific platforms.
MSD's therapeutics-focused venture fund backs early-stage, including seed-stage, drug development companies. It emphasizes sustained capital, board-level partnership, and scientific support from concept toward clinical proof of concept.
Best fit: preclinical therapeutics and breakthrough drug platforms, rather than general engineering deep tech.
Traditional venture capital isn't always the best sole source of funding for a 7–15-year R&D program. Depending on your technology, consider:
Strategic corporate investors: Companies with a commercial reason to see your technology succeed may offer investment alongside pilot projects, licensing, or development partnerships.
Government R&D grants and contracts: In the US, programs such as SBIR/STTR can fund technical milestones without immediate equity dilution, subject to program eligibility.
Specialist life-sciences funds: If you're developing therapeutics, Lightstone and MRL Ventures are relevant starting points. For broader biotech venture funding, a16z Bio + Health announced a $500 million fund with Eli Lilly in January 2025, designed to take a long-term view of emerging biological science.
How to tell whether a fund is genuinely patient
When you speak with potential investors, ask:
Fund life: How long can the fund hold investments, and does it have flexibility to extend?
Follow-on capacity: Does it reserve enough capital to finance several rounds before commercialization?
Technical milestones: Will it support progress measured by validated prototypes, experiments, or regulatory milestones rather than revenue alone?
Portfolio evidence: Has it backed companies with comparable R&D timelines, including through delays or difficult financing environments?
Exit expectations: Does it expect a conventional venture exit within a fixed window, or can it support a longer path through strategic partnerships and commercialization?
A fund can be patient about technology while still having a relatively short financial horizon. Ask for concrete examples of how it handled delays in previous portfolio companies.
Let's narrow this to the investors most likely to fund your startup
The best shortlist will depend heavily on your technology and how far you've progressed.
What are you building?
AI / computational deep tech
Quantum / semiconductors / photonics
Advanced materials / hardware
Energy / climate / industrial tech
Biotech / therapeutics / medtech
Aerospace / robotics / defense
Other deep tech
Current stage
Pre-seed / lab-stage
Seed / working prototype
Series A / pilot validation
Growth / early commercialization
Expected time to commercialization
3–5 years
7–10 years
10+ years
Where are you seeking investors?
US
Europe / UK
Global
Target raise
Under $2M
$2M–$10M
$10M–$30M
$30M+
[Find matching investors]
With those details, I can narrow the list to funds with a relevant technical thesis, suitable check sizes, and evidence that they can support a long R&D journey—not just generalist VCs that occasionally invest in deep tech.
Lux Capital : Managing multi-billion dollar vehicles (such as their recent $1.5B Fund IX commitments), Lux specializes in turning "sci-fi into sci-fact," investing heavily across physical sciences, deep tech, defense, and life sciences with the conviction required for multi-year horizons.[](https://www.luxcapital.com/news/announcing-lux-ventures-ix)
Prime Movers Lab : Invests in breakthrough scientific startups (energy, transportation, human augmentation, agriculture) that reinvent foundational human industries, explicitly advertising a long-term outlook to match scientific timelines.
Lowercarbon Capital : Focused strictly on climate tech and hard science interventions to slash emissions or remove carbon, managing substantial funds with a high tolerance for regulatory and physical R&D timelines.
Breakthrough Energy Ventures (BEV) : Backed by global titans, BEV was built specifically to finance tough energy and climate transitions that standard 7-to-10-year venture funds cannot support due to protracted commercialization paths.
Strategic Corporate VCs (CVCs) & Sovereign/Gov Funds : Entities like In-Q-Tel (IQT) for national security/defense, or regional entities like the UK National Security Strategic Investment Fund (NSSIF) or various ARPA-E/SBIR/STFC government-backed vehicles, offer non-dilutive or ultra-patient capital aligned with national interests rather than quarterly LP returns.
If you tell me your specific vertical (e.g., nuclear fusion, quantum computing, advanced materials, or biotech) and what funding stage you are at (Pre-Seed vs. Series A), I can help you narrow down the exact funds or non-dilutive grants best aligned with your milestones.
Yes. For a deep-tech company where commercialization may take 7–15+ years, I’d look beyond conventional early-stage VC and prioritize investors whose strategy, fund structure, or portfolio history accommodates extended technical de-risking.
Firms I’d put on the initial outreach list
Firm
Why it fits long R&D cycles
Particularly relevant for
DCVC
One of the clearest deep-tech specialists. It invests from incubation/pre-seed through later stages and explicitly describes maintaining reserves to support companies across the long gap between early innovation and market dominance.
Built around frontier science and technology. Its latest $1.5B fund says it can support companies from the first $100K through the last $100M and across the full company-building arc.
Physical sciences, biotech, aerospace, defense, advanced engineering, AI
Prime Movers Lab
Explicitly targets breakthrough scientific startups and technical founders, with unusually hands-on support for commercialization.
Energy, transportation, infrastructure, manufacturing, agriculture, human augmentation
Capital 2B
Explicitly says it backs deep-tech/IP companies when they're "too early," provides patient capital, and invests pre-seed through Series A.
Fundamental science, materials, physical systems, computational/biological technologies
Next Wave Partners
Very explicit "patient capital" positioning and structures designed around how deep tech develops rather than conventional venture timelines.
Autonomous systems and physical-world technology
Black Forest Ventures
Focuses specifically on scientists, engineers and industrial founders, with an explicit long-term approach to physical technologies, regulation and scaling.
Industrial/deep tech, physical infrastructure, hard engineering
KOMPAS VC
Specializes in industrial transformation and describes its capital as patient, with support from early traction through commercial scale. Its current Fund II is €160M.
Industrial tech, manufacturing, built environment, climate/industrial decarbonization
Martlet Capital / EMV Capital
Explicitly describes itself as providing patient capital to early-stage deep-tech and life-sciences B2B companies.
Deep tech, life sciences, Cambridge/UK ecosystem
Arcas Ventures
Calls its strategy "patient capital for impatient founders," investing at pre-seed/seed with follow-on capacity.
European deep tech, materials, space, computational science, medtech
Uniseed
Particularly interesting if you're university/CSIRO-connected. It explicitly defines deep tech around long R&D, IP, manufacturing and regulatory timelines and provides later-stage follow-on capital.
University spinouts, biotech, quantum, advanced materials, energy, robotics, aerospace
"Patient capital" doesn't necessarily mean a 15-year venture fund. Even deep-tech VCs generally operate within finite fund lives. What matters is whether they have:
large follow-on reserves rather than expecting you to raise a new round every 18–24 months;
a demonstrated willingness to fund technical milestones rather than revenue milestones;
experience financing companies through multiple difficult development stages;
partners who understand regulatory, manufacturing and scientific risk;
access to non-VC capital such as government grants, strategic investors and project finance.
DCVC is particularly interesting on this dimension: its own materials emphasize the need for reserves to carry companies from early innovation toward market dominance.
I'd also consider the financing architecture
For genuinely long-cycle technology—say fusion, novel semiconductors, quantum hardware, new materials, advanced therapeutics, aerospace, robotics hardware, or industrial biotech—I wouldn't necessarily try to fund the entire R&D period with ordinary VC.
A stronger structure can be:
VC + non-dilutive R&D capital + strategic/corporate capital + eventual project/growth financing.
That lets the VC fund company-building while grants and strategic partners absorb some of the expensive technical development. The right investor therefore isn't merely "who has the longest holding period?" but who has successfully assembled this capital stack before?
One interesting caution: Lux itself has explicitly argued that some technologies with 15–20-year commercialization timelines don't fit conventional VC economics, despite being a major deep-tech investor. www.luxcapital.com That's a useful reminder that even excellent deep-tech VCs may want to see a credible sequence of intermediate value-creating milestones.
If you tell me (1) your technology/sector, (2) current TRL or development stage, (3) how many years until first commercial revenue, and (4) roughly how much capital you need before that point, I can narrow this to 5–8 specific funds and identify the partners/investors who are most relevant to your particular technology, rather than giving you a generic deep-tech list.
Prominent venture firms and specialized funds known for providing patient capital to deep tech, hard tech, and long-timeline R&D ventures include the following:
Prime Movers Lab : Invests in breakthrough scientific startups inventing transformational technologies (energy, longevity, manufacturing, and transportation). They explicitly position themselves as long-term partners capable of supporting companies through extensive scientific validation and commercialization.
Breakthrough Energy Ventures (BEV) : Backed by a coalition of global investors, BEV finances cutting-edge innovations in clean energy and climate technology. They are purpose-built for multi-decade timelines, recognizing that decarbonization technologies require extensive R&D and infrastructure scale-up.
Founders Fund : Known for making contrarian, high-conviction bets on hard tech, aerospace, and defense (e.g., SpaceX, Anduril ). They have a long-standing appetite for foundational technologies that require an extended runway before market entry.
Foundry : Frequently structures their approach to support foundational ecosystems and longer-term innovation horizons, often operating with structural flexibility compared to traditional fast-turnaround SaaS funds.
